Novo Nordisk Sinks 6% on Strategy Day Jitters: Can a Rebranded Company Outrun a Shrinking Growth Story

Shares plunged 6.1% to $40.58 as Novo Nordisk — now rebranding simply as "Novo" — opened its Capital Markets Day in London, with investors demanding answers about how the Danish drugmaker plans to grow again after a bruising stretch. Products like Ozempic and Wegovy once propelled the company's market cap past $600 billion. Today it trades roughly 32% below its 52-week high, and NVO has fallen about 12% in 2026 after losing more than half its value in 2025, its worst year since 1984.

  • The Pricing Vise That Won't Loosen. The core problem is simple: Novo's drugs are getting cheaper, and not by choice. The company's weak 2026 outlook reflects pricing headwinds in the U.S., with management directly referencing the impact of President Trump's Most Favored Nation policy; in November 2025, Novo struck a White House deal that slashed Wegovy and Ozempic prices. The result: adjusted sales growth for 2026 is now expected to be -4% to -12% at constant exchange rates. Revenue is shrinking, not slowing — a critical distinction for shareholders.

  • Eli Lilly Is Winning the Next Round. Lilly's obesity pill, orforglipron (marketed as Foundayo), was approved by the FDA in April, setting up fierce competition against Novo's Wegovy pill. Meanwhile, Novo's experimental CagriSema combination failed to control blood sugar as well as Lilly's tirzepatide in a head-to-head trial , undermining a key pipeline bet. Lilly trades at 27 times expected earnings versus Novo's 11 times — a valuation gap that reflects how differently the market views their trajectories.

  • 9,000 Job Cuts Buy Time, Not Growth. Novo announced about 9,000 job cuts — 11% of its workforce — to save 8 billion Danish kroner annually by end of 2026. Cost-cutting can protect profit margins, but it cannot replace the top-line acceleration investors need. The CMD outlined 2030 ambitions including " grow and diversify pipeline, drive sustainable growth, deliver attractive returns ," but those targets are explicitly not financial guidance. A pipeline asset called zenagamtide — which combines two hunger-suppressing mechanisms — is entering late-stage trials with potential peak sales estimated at $8–12 billion , but it won't contribute revenue for years.

  • Morgan Stanley's Downgrade Set the Tone. On September 11, Morgan Stanley cut Novo to Underweight with a $40 price target — almost exactly where shares sit today. The broader analyst consensus remains Hold, with a $64.94 average target , but that gap shows deep disagreement about whether the stock is a value trap or a turnaround candidate. Today's sell-off, against a rising broader market, suggests investors found the strategy presentation short on near-term catalysts.